Business
Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS).
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)\n\n\n\n\n\nAmarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)\nPR Newswire\nSAN FRANCISCO, February 3, 2016\n\n\n\nSAN FRANCISCO, February 3, 2016 /PRNewswire/ --\n\nAmarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that its wholly-owned subsidiary Cutanogen Corporation has received two Intent to Grant a Patent notices from the European Patent Officer for Engineered Skin Substitute (ESS). The notices cover the parent patent application entitled \"A method of producing a cultured skin device\" and an associated divisional patent filing. Amarantus expects both patents to issue later in 2016, adding key elements to our strong barrier-to-entry strategy for this innovative technology.\n\nESS represents a revolutionary cell therapy program that holds promise for treating serious dermatological conditions, such as severe burns in adults and children, for which the standard of care (autologous skin grafting) yields mixed results. ESS is positioned to overcome many of the shortcomings of autologous grafting by culturing a small sample of a patient's own skin cells in the lab to form tissue that is intended to cover deeply wounded areas very efficiently. ESS has received orphan drug designation from the US FDA for the treatment of full thickness burns covering over 50% total body surface area.\n\nESS may also be applicable to conditions such as Giant Congenital Melanocytic Nevus, for which Amarantus has also applied for an orphan drug and rare pediatric disease designations. The Company is evaluating various options, including strategic transactions, to move this groundbreaking program towards marketing approval.\n\n\"We are pleased to see the continued development of the Company's intellectual property portfolio surrounding ESS,\" said Gerald E. Commissiong, President & CEO of Amarantus. \"With certain patents covering ESS in a number of key jurisdictions throughout the world already issued, the pending addition of this new piece of intellectual property underscores the strength of our proprietary position in the manufacture of auto...